Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Executive Summary
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.
You may also be interested in...
Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone
The latest drug development news and highlights from our US FDA Performance Tracker.